Novo Nordisk Stock: Is It Still a Smart Buy?

Novo Nordisk's stock has declined nearly 18% year-to-date amid growing competition in the obesity drug market, particularly from Eli Lilly's Zepbound, which has captured a significant market share; Goldman Sachs estimates Novo Nordisk now holds 51% of the $28 billion market. While Novo Nordisk faces headwinds, including past semaglutide shortages and a CEO transition, the company is investing in production capacity through the $16.5 billion acquisition of Catalent and pursuing new indications for Wegovy, with analysts projecting the obesity drug market to reach $150 billion by 2035.

Analysis

Novo Nordisk's (NVO) stock has experienced a nearly 18% decline year-to-date, reflecting investor concerns over escalating competition in the lucrative obesity drug market, primarily from Eli Lilly's (LLY) Zepbound. A Goldman Sachs analysis indicates Novo Nordisk currently holds a 51% share of the approximately $28 billion market, with Eli Lilly capturing the remaining 49%. Novo Nordisk has navigated several headwinds, including a past shortage of semaglutide, Wegovy's main ingredient, which, though officially over, underscored supply chain vulnerabilities. Further contributing to investor sentiment is the announced departure of its long-serving CEO, Lars Fruergaard Jørgensen, in mid-May. The article also highlights that a head-to-head clinical trial initiated by Eli Lilly, comparing Zepbound with Wegovy, was framed among "competitive blows," despite concurrently reporting that study results from last December indicated "notably more significant weight loss for participants using Wegovy." In response to market pressures, Novo Nordisk strategically acquired contract drug manufacturer Catalent for $16.5 billion to enhance direct control over Wegovy production. The company is also actively pursuing label expansions for Wegovy, recently securing FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), and developing it for other ailments, even as its next-generation obesity treatment, CagriSema, was deemed a "flop." Despite these challenges, the obesity drug market is projected for explosive growth, with Morgan Stanley forecasting a peak market size of $150 billion by 2035, a significant uplift from its previous $105 billion estimate and substantially greater than the $24 billion estimated sales for 2024.

Key Decisions for Investors

• Investors should carefully evaluate Novo Nordisk's current valuation following its stock price decline against the substantial growth potential of the obesity drug market, while rigorously assessing the impact of intensifying competition, particularly from Eli Lilly, on future market share and profitability.
• The successful and timely integration of Catalent is a critical factor to monitor, as enhanced in-house production capacity for Wegovy is pivotal for Novo Nordisk to meet robust global demand, mitigate supply chain risks, and defend its market leadership position.
• Closely track Novo Nordisk's R&D pipeline, including further label expansions for Wegovy and the progress of other drug candidates, as well as the strategic direction and execution under new leadership post the CEO transition, to gauge long-term, diversified growth drivers.
• Acknowledge the highly optimistic market size projections for GLP-1 drugs, but remain vigilant regarding potential risks such as increased pricing pressures from payers or governments, new regulatory hurdles, or disruptive clinical trial outcomes from emerging competitors that could reshape the competitive landscape.